These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34890630)

  • 1. Studies on the pH-Dependent Solubility of Various Grades of Calcium Phosphate-based Pharmaceutical Excipients.
    Wagner M; Hess T; Zakowiecki D
    J Pharm Sci; 2022 Jun; 111(6):1749-1760. PubMed ID: 34890630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of controlled-release baclofen matrix tablets. II. Influence of some hydrophobic excipients on the release rate and in vitro evaluation.
    Abdelkader H; Youssef Abdalla O; Salem H
    AAPS PharmSciTech; 2008; 9(2):675-83. PubMed ID: 18500558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pectin/anhydrous dibasic calcium phosphate matrix tablets for in vitro controlled release of water-soluble drug.
    Mamani PL; Ruiz-Caro R; Veiga MD
    Int J Pharm; 2015 Oct; 494(1):235-43. PubMed ID: 26276258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium phosphates in pharmaceutical tableting. 1. Physico-pharmaceutical properties.
    Schmidt PC; Herzog R
    Pharm World Sci; 1993 Jun; 15(3):105-15. PubMed ID: 8348106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of formulation solubility and hygroscopicity on disintegrant efficiency in tablets prepared by wet granulation, in terms of dissolution.
    Johnson JR; Wang LH; Gordon MS; Chowhan ZT
    J Pharm Sci; 1991 May; 80(5):469-71. PubMed ID: 1880728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of formulation effects in the dissolution of ibuprofen pellets.
    Costa FO; Pais AA; Sousa JJ
    Int J Pharm; 2004 Feb; 270(1-2):9-19. PubMed ID: 14726117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of fujicalin, a new modified anhydrous dibasic calcium phosphate for direct compression: comparison with dicalcium phosphate dihydrate.
    Schlack H; Bauer-Brandl A; Schubert R; Becker D
    Drug Dev Ind Pharm; 2001 Sep; 27(8):789-801. PubMed ID: 11699830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aging of tablets made with dibasic calcium phosphate dihydrate as matrix.
    Lausier JM; Chiang CW; Zompa HA; Rhodes CT
    J Pharm Sci; 1977 Nov; 66(11):1636-7. PubMed ID: 915749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why are aqueous suspensions of the coarse grades of anhydrous calcium hydrogen phosphate acidic?
    Eyjolfsson R
    Pharmazie; 2010 Jul; 65(7):527. PubMed ID: 20662325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.
    Riis T; Bauer-Brandl A; Wagner T; Kranz H
    Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
    Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the effects of excipients on the powder flow characteristics of theophylline anhydrous powder formulations.
    Nagel KM; Peck GE
    Drug Dev Ind Pharm; 2003 Mar; 29(3):277-87. PubMed ID: 12741609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of excipient type and level on drug release from controlled release tablets containing HPMC.
    Williams RO; Reynolds TD; Cabelka TD; Sykora MA; Mahaguna V
    Pharm Dev Technol; 2002 May; 7(2):181-93. PubMed ID: 12066573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug.
    Kranz H; Le Brun V; Wagner T
    Int J Pharm; 2005 Aug; 299(1-2):84-91. PubMed ID: 15970409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incompatibility of croscarmellose sodium with alkaline excipients in a tablet formulation.
    Bindra DS; Stein D; Pandey P; Barbour N
    Pharm Dev Technol; 2014 May; 19(3):285-9. PubMed ID: 23528069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
    Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium phosphates in pharmaceutical tableting. 2. Comparison of tableting properties.
    Schmidt PC; Herzog R
    Pharm World Sci; 1993 Jun; 15(3):116-22. PubMed ID: 8348107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of an ispaghula based directly compressible matrixing agent for controlled release.
    Lalwani AN; Parikh JR
    Acta Pharm; 2008 Sep; 58(3):309-16. PubMed ID: 19103567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of binder attributes on binder effectiveness in a continuous twin screw wet granulation process via wet and dry binder addition.
    Vandevivere L; Denduyver P; Portier C; Häusler O; De Beer T; Vervaet C; Vanhoorne V
    Int J Pharm; 2020 Jul; 585():119466. PubMed ID: 32464227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissolution enhancement of atorvastatin calcium by co-grinding technique.
    Prabhu P; Patravale V
    Drug Deliv Transl Res; 2016 Aug; 6(4):380-91. PubMed ID: 26712124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.